Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Endocrine 1

Conditions

Carcinoma, Renal Cell 62Prostatic Neoplasms 35Kidney Neoplasms 18Carcinoma, Transitional Cell 17Melanoma 15Urinary Bladder Neoplasms 14Neoplasm Metastasis 12Carcinoma, Non-Small-Cell Lung 12Clear-cell metastatic renal cell carcinoma 11Colorectal Neoplasms 9Neoplasms 8Carcinoma, Hepatocellular 8Squamous Cell Carcinoma of Head and Neck 7Triple Negative Breast Neoplasms 6Ovarian Neoplasms 6Lung Neoplasms 6Uterine Cervical Neoplasms 5Stomach Neoplasms 5Pancreatic Neoplasms 5Urogenital Neoplasms 4Small Cell Lung Carcinoma 4Endometrial Neoplasms 4Carcinoma, Merkel Cell 4Urethral Neoplasms 3Penile Neoplasms 3Neuroblastoma 3Liver Neoplasms 3Brain Neoplasms 3Wilms Tumor 2Ureteral Neoplasms 2

Interventions

pembrolizumab 3belinostat 2enzalutamide 1apalutamide 1abiraterone 1Quality of Life 1Patient Reported Outcome Measures 1PT-100 dipeptide 1Nivolumab 1Molecular Diagnostic Techniques 1Ipilimumab 1Immunotherapy 1Fluorouracil 1Drug Therapy 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × Ipilimumab × Genitourinary × Clear all
NCT03333616 2026-01-21

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
100 enrolled
EndocrineGenitourinary

Penile Neoplasms, Urogenital Neoplasms, Adrenocortical Carcinoma, Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡